370 related articles for article (PubMed ID: 31831042)
1. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study.
Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X
Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
[TBL] [Abstract][Full Text] [Related]
3. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R; Trad Wadsworth J; Higgins K; Beitler JJ; Ramalingam SS; Owonikoko TK; Khuri FR; Shin DM; Behera M; Saba NF
Head Neck; 2019 May; 41(5):1490-1498. PubMed ID: 30835900
[TBL] [Abstract][Full Text] [Related]
4. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
[TBL] [Abstract][Full Text] [Related]
6. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis.
Tang WH; Sun W; Long GX
Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005
[TBL] [Abstract][Full Text] [Related]
7. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Schüttrumpf L; Marschner S; Scheu K; Hess J; Rietzler S; Walch A; Baumeister P; Kirchner T; Ganswindt U; Zitzelsberger H; Belka C; Maihoefer C
Radiat Oncol; 2020 Jan; 15(1):7. PubMed ID: 31906998
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.
Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z
Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
Haehl E; Rühle A; David H; Kalckreuth T; Sprave T; Stoian R; Becker C; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Feb; 15(1):31. PubMed ID: 32019576
[TBL] [Abstract][Full Text] [Related]
11. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).
Ghadjar P; Pöttgen C; Joos D; Hayoz S; Baumann M; Bodis S; Budach W; Studer G; Stromberger C; Zimmermann F; Kaul D; Plasswilm L; Olze H; Bernier J; Wust P; Aebersold DM; Budach V
Strahlenther Onkol; 2016 Aug; 192(8):552-60. PubMed ID: 27323753
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection.
Boros A; Blanchard P; Dade A; Gorphe P; Breuskin I; Even C; Nguyen F; Deutsch E; Bidault F; Janot F; Temam S; Mirghani H; Tao Y
Laryngoscope; 2021 Mar; 131(3):E846-E850. PubMed ID: 32833260
[TBL] [Abstract][Full Text] [Related]
13. Accelerated Radiotherapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancers: Evaluation of Response and Compliance.
Mashhour K; Atef H; Selim A; A Moez M; Zawam H; Abo-Madyan Y
Asian Pac J Cancer Prev; 2020 May; 21(5):1399-1407. PubMed ID: 32458648
[TBL] [Abstract][Full Text] [Related]
14. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
15. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
16. The change in circulating tumor cells before and during concurrent chemoradiotherapy is associated with survival in patients with locally advanced head and neck cancer.
Wang HM; Wu MH; Chang PH; Lin HC; Liao CD; Wu SM; Hung TM; Lin CY; Chang TC; Tzu-Tsen Y; Hsieh JC
Head Neck; 2019 Aug; 41(8):2676-2687. PubMed ID: 30903634
[TBL] [Abstract][Full Text] [Related]
17. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
19. Lymph node ratio as a prognostic factor for survival in patients with head and neck squamous cell carcinoma.
Sano D; Yabuki K; Takahashi H; Arai Y; Chiba Y; Tanabe T; Nishimura G; Oridate N
Auris Nasus Larynx; 2018 Aug; 45(4):846-853. PubMed ID: 29203318
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
